Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

JAZZ stock hub

Jazz Pharmaceuticals plc has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

JAZZis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

14.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

JAZZ

In the news

Latest news · JAZZ

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9.2

P25 12.3P50 18.4P75 33.1

Trailing P/E481

P25 14.9P50 23.2P75 38.5

ROE0.7

P25 -105.6P50 -46.5P75 -3.1

ROIC18

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All JAZZ market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

259

Groups with data

Currency

USD

Showing 259 of 259 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001232524
Company name	Jazz Pharmaceuticals plc
Country	Ireland
Country code	US
Cusip	G50871105
Employees	2,890
Employees Change	90%
Employees Change Percent	3.21
Enterprise value	$16.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2007-06-01
Isin	IE00B4Q5ZN47
Last refreshed	2026-05-10
Market cap	$14.2B
Market cap category	Large-Cap
Price	$226
Price currency	USD
Rev Per Employee	1,535,877.51x
Sector	Healthcare
Sic	2834
Symbol	JAZZ
Website	https://www.jazzpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.21%
EV Earnings	567.34x
EV Sales Forward	3.65x
EV/EBIT	12.9x
EV/EBITDA	8.32x
EV/FCF	13.16x
EV/Sales	3.76x
FCF yield	8.96%
Forward P/E	9.24x
P/B ratio	3.12x
P/E ratio	481.01x
P/S ratio	3.19x
PE Ratio10 Y	45.46x
PE Ratio3 Y	74.94x
PEG ratio	0.17x
PS Forward	3.09x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	29.18%
EBITDA Margin	45.24%
FCF margin	28.6%
Gross margin	91.5%
Gross Profit	$4.1B
Gross Profit Growth	8.42%
Gross Profit Growth Q	18.13%
Gross Profit Growth3 Y	5.54%
Gross Profit Growth5 Y	12.28%
Net Income	$29.5M
Net Income Growth	-93.89%
Net Income Growth Quarters	3%
Net Income Growth Years	0%
Net Income Growth5 Y	-43.65%
Pretax Margin	-4.94%
Profit Margin	0.66%
Profit Per Employee	$10,191
ROA	6.92
Roa5y	4.45
ROCE	13.48
ROE	0.68
Roe5y	0.6
ROIC	18.02
Roic5y	10.46

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	4.58%
Cagr15y	14.59%
Cagr1y	122.71%
Cagr3y	17.44%
Cagr5y	5.28%
EPS Growth	-93.71
EPS Growth Quarters	3
EPS Growth Years	0
EPS Growth5 Y	-44.62
FCF Growth	-16.11%
FCF Growth Q	-6.59%
FCF Growth3 Y	-2.34%
FCF Growth5 Y	7.14%
OCF Growth	-14.39%
OCF Growth Q	-5.03%
OCF Growth10 Y	8.56%
OCF Growth3 Y	-1.21%
OCF Growth5 Y	7.91%
Revenue Growth	9.2x
Revenue Growth Q	19.06x
Revenue Growth Quarters	4x
Revenue Growth Years	20x
Revenue Growth3 Y	5.89x
Revenue Growth5 Y	12.75x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.38
Assets	$11.9B
Cash	$2.9B
Current Assets	$4.6B
Current Liabilities	$2.2B
Debt	$5.4B
Debt EBITDA	$2.66
Debt Equity	$1.2
Debt FCF	$4.27
Equity	$4.5B
Interest Coverage	4.93
Liabilities	$7.3B
Long Term Assets	$7.3B
Long Term Liabilities	$5.1B
Net Cash	$-2.5B
Net Cash By Market Cap	$-17.95
Net Debt EBITDA	$1.27
Net Debt Equity	$0.56
Net Debt FCF	$2
Tangible Book Value	$-1.5B
Tangible Book Value Per Share	$-23.55
WACC	5.23

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.04
Inventory Turnover	0.81
Net Working Capital	$507.6M
Quick ratio	1.65
Working Capital	$2.3B
Working Capital Turnover	$1.69

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.13%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	56.42%
1Y total return	122.59%
200-day SMA	159
3Y total return	61.97%
50-day SMA	193.9
50-day SMA vs 200-day SMA	50over200
5Y total return	29.33%
All Time High	230.4
All Time High Change	-2%
All Time High Date	2026-05-06
All Time Low	0.52
All Time Low Change	43,742.72%
All Time Low Date	2009-04-22
ATR	6.26
Beta	0.27
Beta1y	0.45
Beta2y	0.68
Ch YTD	32.82
High	230
High52	230.4
High52 Date	2026-05-06
High52ch	-2%
Low	223.3
Low52	97.5
Low52 Date	2025-05-08
Low52ch	131.58%
Ma50ch	16.45%
Premarket Change Percent	-0.42
Premarket Price	$226
Premarket Volume	256
Price vs 200-day SMA	41.98%
RSI	73.02
RSI Monthly	76.46
RSI Weekly	76.29
Sharpe ratio	2.22x
Sortino ratio	4.84
Total Return	5.13%
Tr YTD	32.82
Tr15y	671.4%
Tr1m	18.25%
Tr1w	11.38%
Tr3m	36.43%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	15
Analyst Count Top	10
Analyst Price Target Top	$233
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$4.49
Earnings EPS Estimate Growth	167.3
Earnings Revenue Estimate	977,606,280x
Earnings Revenue Estimate Growth	8.88x
Operating Income	$1.3B
Operating Income Growth	76.72
Operating Income Growth3 Y	14.38
Operating Income Growth5 Y	10.71
Operating margin	29.18
Price target	$227
Price Target Change	$0.62
Price Target Change Top	$3.19

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60,796,569%
Float Percent	96.9%
Net Borrowing	-31,000,000
Shares Insiders	3.01%
Shares Institutions	99.21%
Shares Out	62,742,820
Shares Qo Q	4.2%
Shares Yo Y	-5.13%
Short Float	8.62%
Short Ratio	6.14
Short Shares	8.35

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$971.7M
Average Volume	998,101.7x
Bv Per Share	72.29
CAPEX	$-64.6M
Ch10y	56.42
Ch15y	671.4
Ch1m	18.25
Ch1w	11.38
Ch1y	122.6
Ch3m	36.43
Ch3y	61.97
Ch5y	29.33
Ch6m	72.15
Change	-0.52%
Change From Open	-1.29
Close	227
Days Gap	0.78
Depreciation Amortization	712,897,000
Dollar Volume	167,364,805.4
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$1.3B
EBITDA	$2B
EPS	$0.47
F Score	6
FCF	$1.3B
FCF EV Yield	7.6x
FCF Per Share	$20.24
Financing CF	-138,380,000
Fiscal Year End	December
Founded	2,003
Goodwill	1,805,000,000
Graham Number	27.7206
Graham Upside	-87.72
Income Tax	$-248.5M
Investing CF	-1,217,813,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-24
Lynch Fair Value	$2.36
Lynch Upside	-98.95
Ma150	171
Ma150ch	32.04%
Ma20	205.5
Ma20ch	9.88%
Net CF	-17,565,000
Next Earnings Date	2026-08-04
Open	228.7
Optionable	Yes
P FCF Ratio	11.16
P OCF Ratio	10.62
Position In Range	36.79
Post Close	225.8
Postmarket Change Percent	-1.04
Postmarket Price	$223
Ppne	258,900,000
Pre Close	227
Price Date	2026-05-08
Price EBITDA	$7.05
Relative Volume	0.74x
Revenue	4,438,686,000x
SBC By Revenue	6.71x
Share Based Comp	297,933,000
Tax By Revenue	-5.6x
Tr6m	72.15%
Volume	741,241
Z Score	1.77

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does JAZZ pay a dividend?

Capital-return profile for this ticker.

Performance

JAZZ stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns JAZZ?

Insider, institutional, and short-interest positioning.

Institutional ownership

+99.2%

Float: +96.9% of shares outstanding

Insider ownership

+3.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

JAZZ momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

73.0

Above 70: short-term overbought

Price vs 200-day MA

+42.0%

50/200-day relationship not available

Beta (5Y)

0.27

Less volatile than the market

Sharpe ratio

2.22

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About JAZZ

Hub-level FAQ points readers to the deeper analysis pages.

What is the current JAZZ stock rating?

Jazz Pharmaceuticals plc is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full JAZZ analysis?

The full report lives at /stocks/JAZZ/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for JAZZ?

The latest report frames JAZZ around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the JAZZ page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.